{"id":3966,"date":"2026-10-28T09:00:00","date_gmt":"2026-10-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3966"},"modified":"2026-10-28T20:49:44","modified_gmt":"2026-10-29T00:49:44","slug":"selective-mettl1-inhibitor-extends-rna-target-validation","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3966","title":{"rendered":"Selective METTL1 Inhibitor Extends RNA Target Validation"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Yankova laboratory (academic)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication<\/p>\n

Modality<\/strong><\/p>\n

Small-molecule RNA-modification enzyme inhibitor<\/p>\n

Asset<\/strong><\/p>\n

STM9005<\/p>\n

Target<\/strong><\/p>\n

METTL1 (tRNA m7G methyltransferase)<\/p>\n

Disease Area<\/strong><\/p>\n

AML and solid tumors (preclinical)<\/p>\n

Summary<\/h4>\n

A peer-reviewed Nature paper published online 28 October reports STM9005, a selective catalytic METTL1 inhibitor, with cellular tRNA-m7G target engagement and activity in AML and solid-tumor mouse models. This is a preclinical target and chemistry advance, not clinical efficacy.<\/p>\n

The authors report a tRNA-Val m7G cellular IC50 of 34 nM, crystallographic binding at the METTL1 SAM pocket, selective changes in modified tRNAs, AML differentiation, lower marrow leukemia burden and longer survival in a patient-derived AML xenograft. Mouse plasma half-life was about one hour; twice-daily dosing was used in key efficacy models. Another METTL1 inhibitor and AML mechanism were published earlier in 2026, so first-in-class language is the authors\u2019 claim rather than uncontested priority.<\/p>\n

Deep Analysis<\/h4>\n

Orthogonal structure, methylation and phenotype experiments strengthen causal attribution to the METTL1-WDR4 axis. The opportunity is to perturb codon-biased oncogenic translation in hematologic malignancy. Yet broad tRNA modification raises normal progenitor and tissue-repair risk; short mouse studies and absence of measured hematopoietic reserve cannot establish chronic therapeutic index. A one-hour half-life and intensive dosing point to medicinal-chemistry and exposure challenges. Predictive biomarkers, resistance via translational compensation, human marrow penetration, off-target methyltransferase profiling and scalable synthesis remain open.<\/p>\n

Company and Product Background<\/h4>\n

METTL1-WDR4 installs N7-methylguanosine on selected tRNAs, influencing translation. AML and other cancers can depend on this activity; STM9005 inhibits METTL1 catalytic function.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> catalytic METTL1 inhibition is a tractable anticancer modality, supported by engagement and multiple in-vivo models.<\/li>\n
  • Interpretation B:<\/strong> sensitivity reflects model-specific translation stress, with limited clinical window.<\/li>\n
  • Upgrade<\/strong> with human AML organoids, normal-HSC selectivity and durable oral exposure. Downgrade<\/strong> with marrow toxicity or loss of activity across genetically diverse samples. Failure at tolerated exposures in independent PDX models would falsify<\/strong> broad therapeutic claims.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this validates a druggable RNA-modification axis and creates partnering interest, but does not make STM9005 a treatment-ready candidate.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: positive preclinical validation; clinical uncertain. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Nature paper published online 28 October reports STM9005, a selective catalytic METTL1 inhibitor, with cellular tRNA-m7G target engagement and activity in AML and solid-tumor mouse models. This is a preclinical target and…<\/p>\n","protected":false},"author":1,"featured_media":3967,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,1279,1133,1280,1281],"class_list":["post-3966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-mettl1","tag-nature","tag-stm9005","tag-trna-modification"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3966"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3966\/revisions"}],"predecessor-version":[{"id":3982,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3966\/revisions\/3982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3967"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}